• Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapy
  • Results from the Phase 1b/2 EPCORE NHL-2 trial show fixed-duration epcoritamab plus standard of care R-mini-CHOP demonstrated sustained minimal residual disease (MRD) negativity and durable remissions in elderly patients with newly diagnosed DLBCL ineligible for full dose R-CHOP
  • Data were presented at the 2026 European Hematology Association (EHA) Congress